Alnylam Pharma (DUL) Stock Forecast & Price Target

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DUL Analyst Ratings

Strong Buy

15 Buy

3 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Alnylam

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DUL Stock 12 Month Forecast

Average Price Target

€337.45

▲(35.36% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Alnylam Pharma in the last 3 months. The average price target is €337.45 with a high forecast of €477.81 and a low forecast of €199.81. The average price target represents a 35.36% change from the last price of €249.30.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"198":"€198","268":"€268","338":"€338","408":"€408","478":"€478"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":477.8071595,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€477.81</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":337.451306396875,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€337.45</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":199.8102667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€199.81</span>\n  </div></div>","useHTML":true}}],"tickPositions":[198,268,338,408,478],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,269.4,285.43131996153846,301.4626399230769,317.4939598846154,333.5252798461538,349.5565998076923,365.5879197692308,381.6192397307692,397.6505596923077,413.6818796538462,429.7131996153846,445.7445195769231,461.7758395384616,{"y":477.8071595,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,269.4,274.63471587668266,279.86943175336535,285.10414763004803,290.3388635067308,295.57357938341346,300.80829526009614,306.04301113677883,311.2777270134615,316.5124428901442,321.74715876682694,326.9818746435096,332.2165905201923,{"y":337.451306396875,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,269.4,264.0469435923077,258.6938871846154,253.34083077692307,247.98777436923075,242.63471796153846,237.28166155384613,231.92860514615384,226.57554873846152,221.22249233076923,215.8694359230769,210.5163795153846,205.1633231076923,{"y":199.8102667,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":274.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":341,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":377.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":393.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":392.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":396.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":335.4,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":288.8,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":278.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":285.1,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":263.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":256.9,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":269.4,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€477.81

Average Price Target€337.45

Lowest Price Target€199.81

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

Wells Fargo

Not Ranked

Wells Fargo

€327.52→€274.52

Hold

10.12%

Upside

Reiterated

07/31/26

Alnylam Pharma (ALNY) Receives a Hold from Wells Fargo

Faisal Khurshid

Jefferies

€199.81

Hold

-19.85%

Downside

Reiterated

07/31/26

Jefferies Sticks to Their Hold Rating for Alnylam Pharma (ALNY)

Ritu Baral

TD Cowen

€418.73

Buy

67.96%

Upside

Assigned

07/31/26

Analysts Conflicted on These Healthcare Names: Alnylam Pharma (NASDAQ: ALNY), Stryker (NYSE: SYK) and Bicycle Therapeutics (NASDAQ: BCYC)

Paul Matteis

Stifel Nicolaus

€385.72→€276.26

Buy

10.81%

Upside

Assigned

07/31/26

Alnylam price target lowered to $318 from $444 at StifelAlnylam price target lowered to $318 from $444 at Stifel

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

07/31/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Bausch Health Companies (NYSE: BHC)

Martin Auster

Raymond James

€406.57→€364.87

Buy

46.36%

Upside

Reiterated

07/31/26

Alnylam price target lowered to $420 from $468 at Raymond JamesAlnylam price target lowered to $420 from $468 at Raymond James

Jessica Fye

J.P. Morgan

€347.5→€325.78

Buy

30.68%

Upside

Reiterated

07/31/26

Analysts Conflicted on These Healthcare Names: Karyopharm Therapeutics (NASDAQ: KPTI), Baxter International (NYSE: BAX) and Alnylam Pharma (NASDAQ: ALNY)

Eliana Merle

Barclays

€457.83

Buy

83.64%

Upside

Reiterated

07/31/26

Analysts Offer Insights on Healthcare Companies: Mettler-Toledo (NYSE: MTD), AnaptysBio (NASDAQ: ANAB) and Alnylam Pharma (NASDAQ: ALNY)

Michael Ulz

Morgan Stanley

€347.5→€260.62

Hold

4.54%

Upside

Reiterated

07/31/26

Alnylam Pharma (ALNY) Gets a Hold from Morgan Stanley

Kostas Biliouris

Oppenheimer

€434.37→€304.06

Buy

21.97%

Upside

Reiterated

07/31/26

Alnylam price target lowered to $350 from $500 at OppenheimerAlnylam price target lowered to $350 from $500 at Oppenheimer

Myles Minter

William Blair

―

Buy

―

Reiterated

07/30/26

Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (NASDAQ: BCYC), Alnylam Pharma (NASDAQ: ALNY) and Fortrea Holdings Inc. (NASDAQ: FTRE)

Patrick Trucchio

H.C. Wainwright

€351.84→€421.34

Buy

69.01%

Upside

Reiterated

07/30/26

H.C. Wainwright Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

Joseph Stringer

Needham

€443.06→€310.14

Buy

24.40%

Upside

Reiterated

07/30/26

Analysts Offer Insights on Healthcare Companies: Disc Medicine (NASDAQ: IRON) and Alnylam Pharma (NASDAQ: ALNY)

Tazeen Ahmad

Bank of America Securities

€356.18→€300.58

Buy

20.57%

Upside

Reiterated

07/30/26

Alnylam: Buy Rating Reiterated as Long-Term ATTR-CM Opportunity and Amvuttra Leadership Offset Guidance Cuts and Price Target Reduction to $346

Luca Issi

RBC Capital

€386.59→€304.06

Buy

21.97%

Upside

Assigned

07/30/26

RBC Capital Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

Wells Fargo

Not Ranked

Wells Fargo

€327.52→€274.52

Hold

10.12%

Upside

Reiterated

07/31/26

Alnylam Pharma (ALNY) Receives a Hold from Wells Fargo

Faisal Khurshid

Jefferies

€199.81

Hold

-19.85%

Downside

Reiterated

07/31/26

Jefferies Sticks to Their Hold Rating for Alnylam Pharma (ALNY)

Ritu Baral

TD Cowen

€418.73

Buy

67.96%

Upside

Assigned

07/31/26

Analysts Conflicted on These Healthcare Names: Alnylam Pharma (NASDAQ: ALNY), Stryker (NYSE: SYK) and Bicycle Therapeutics (NASDAQ: BCYC)

Paul Matteis

Stifel Nicolaus

€385.72→€276.26

Buy

10.81%

Upside

Assigned

07/31/26

Alnylam price target lowered to $318 from $444 at StifelAlnylam price target lowered to $318 from $444 at Stifel

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

07/31/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Bausch Health Companies (NYSE: BHC)

Martin Auster

Raymond James

€406.57→€364.87

Buy

46.36%

Upside

Reiterated

07/31/26

Alnylam price target lowered to $420 from $468 at Raymond JamesAlnylam price target lowered to $420 from $468 at Raymond James

Jessica Fye

J.P. Morgan

€347.5→€325.78

Buy

30.68%

Upside

Reiterated

07/31/26

Analysts Conflicted on These Healthcare Names: Karyopharm Therapeutics (NASDAQ: KPTI), Baxter International (NYSE: BAX) and Alnylam Pharma (NASDAQ: ALNY)

Eliana Merle

Barclays

€457.83

Buy

83.64%

Upside

Reiterated

07/31/26

Analysts Offer Insights on Healthcare Companies: Mettler-Toledo (NYSE: MTD), AnaptysBio (NASDAQ: ANAB) and Alnylam Pharma (NASDAQ: ALNY)

Michael Ulz

Morgan Stanley

€347.5→€260.62

Hold

4.54%

Upside

Reiterated

07/31/26

Alnylam Pharma (ALNY) Gets a Hold from Morgan Stanley

Kostas Biliouris

Oppenheimer

€434.37→€304.06

Buy

21.97%

Upside

Reiterated

07/31/26

Alnylam price target lowered to $350 from $500 at OppenheimerAlnylam price target lowered to $350 from $500 at Oppenheimer

Myles Minter

William Blair

―

Buy

―

Reiterated

07/30/26

Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (NASDAQ: BCYC), Alnylam Pharma (NASDAQ: ALNY) and Fortrea Holdings Inc. (NASDAQ: FTRE)

Patrick Trucchio

H.C. Wainwright

€351.84→€421.34

Buy

69.01%

Upside

Reiterated

07/30/26

H.C. Wainwright Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

Joseph Stringer

Needham

€443.06→€310.14

Buy

24.40%

Upside

Reiterated

07/30/26

Analysts Offer Insights on Healthcare Companies: Disc Medicine (NASDAQ: IRON) and Alnylam Pharma (NASDAQ: ALNY)

Tazeen Ahmad

Bank of America Securities

€356.18→€300.58

Buy

20.57%

Upside

Reiterated

07/30/26

Alnylam: Buy Rating Reiterated as Long-Term ATTR-CM Opportunity and Amvuttra Leadership Offset Guidance Cuts and Price Target Reduction to $346

Luca Issi

RBC Capital

€386.59→€304.06

Buy

21.97%

Upside

Assigned

07/30/26

RBC Capital Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

ZURAZura Bio

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alnylam Pharma

3 Months

Keay NakaeChardan Capital

Success Rate

25/40 ratings generated profit

Average Return

+5.67%

Copying Keay Nakae's trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +5.67% per trade.

1 Year

Whitney IjemCanaccord Genuity

Success Rate

19/27 ratings generated profit

Average Return

+23.89%

Copying Whitney Ijem's trades and holding each position for 1 Year would result in 70.37% of your transactions generating a profit, with an average return of +23.89% per trade.

2 Years

Keay NakaeChardan Capital

Success Rate

28/40 ratings generated profit

Average Return

+33.44%

Copying Keay Nakae's trades and holding each position for 2 Years would result in 70.00% of your transactions generating a profit, with an average return of +33.44% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DUL Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DUL has received 54 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. DUL average Analyst price target in the past 3 months is 337.45.

Each month's total comprises the sum of three months' worth of ratings.

DUL Financial Forecast

DUL Earnings Forecast

Next quarter’s earnings estimate for DUL is €1.54 with a range of €1.05 to €2.57. The previous quarter’s EPS was €1.05. DUL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year DUL has Performed in-line its overall industry.

DUL Sales Forecast

Next quarter’s sales forecast for DUL is €1.26B with a range of €1.20B to €1.37B. The previous quarter’s sales results were €1.12B. DUL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.23% of the time in the same period. In the last calendar year DUL has Performed in-line its overall industry.

DUL Stock Forecast FAQ

What is DE:DUL’s average 12-month price target, according to analysts?

Based on analyst ratings, Alnylam Pharmaceuticals’s 12-month average price target is 337.45.

What is DE:DUL’s upside potential, based on the analysts’ average price target?

Alnylam Pharmaceuticals has 35.36% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Alnylam Pharmaceuticals a Buy, Sell or Hold?

Alnylam Pharmaceuticals has a consensus rating of Strong Buy, which is based on 15 buy ratings, 3 hold ratings and 0 sell ratings.

What is Alnylam Pharmaceuticals’s share price target?

The average share price target for Alnylam Pharmaceuticals is 337.45. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €477.81 ,and the lowest forecast is €199.81. The average share price target represents 35.36% Increase from the current price of €249.3.

What do analysts say about Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of Alnylam Pharmaceuticals?

To buy shares of DE:DUL, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Alnylam Pharma (DUL) Stock Forecast & Price Target

DUL Analyst Ratings

DUL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Alnylam Pharma

DUL Analyst Recommendation Trends

DUL Financial Forecast

DUL Earnings Forecast

DUL Sales Forecast

DUL Stock Forecast FAQ

Detailed List of Analyst Forecasts